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Summary
Background: Immune checkpoint inhibitors are used in the treatment of multi‐
ple advanced stage cancers but can induce immune‐mediated colitis necessitating 
treatment with immunosuppressive medications. Diagnostic colonoscopy is often 
performed but requires bowel preparation and may delay diagnosis and treatment. 
Sigmoidoscopy can be performed rapidly without oral bowel preparation or sedation.
Aims: Characterize the colonic distribution of immune‐mediated colitis to determine 
the most efficient endoscopic approach.
Methods: A systematic review of checkpoint inhibitor‐induced colitis case reports 
and series was conducted in both PubMed and Embase through 3 January 2017. 
A single centre retrospective chart review of patients who underwent endoscopic 
evaluation for diarrhoea after treatment with a checkpoint inhibitor (ipilimumab, 
nivolumab or pembrolizumab) between 1 January 2011 and 3 January 2017 was per‐
formed. Clinical, endoscopic and histologic data were collected.
Results: A detailed systematic review resulted in 61 studies, in which 226 cases of 
colitis were diagnosed by lower endoscopy (125 colonoscopy, 101 sigmoidoscopy). 
Only four patients had isolated findings proximal to the left colon. In our centre, 31 
patients had histologic features of checkpoint inhibitor‐induced colitis, for which 29 
patients had complete data. The left colon was involved in all cases. Sigmoidoscopy 
would be sufficient to diagnose >98% of reported cases of checkpoint inhibitor‐medi‐
ated colitis diagnosed by lower endoscopy.
Conclusions: Moderate to severe checkpoint inhibitor‐induced colitis involves the 
left colon in the majority of cases (>98%). Sigmoidoscopy should be the initial endo‐
scopic procedure in the evaluation of this condition.
     |  1475WRIGHT eT al.
1  | INTRODUC TION
Immune checkpoint inhibitors are a novel class of biologic therapies 
that enhances T lymphocyte‐mediated anti‐tumour activity through 
inhibition of negative costimulatory molecules such as cytotoxic T 
lymphocyte antigen 4 (CTLA‐4) and programmed cell death pro‐
tein 1 (PD‐1).1 Ipilimumab (a monoclonal antibody against CTLA‐4), 
nivolumab (a monoclonal antibody against PD‐1) and pembrolizumab 
(a monoclonal antibody against PD‐1) were first approved for the 
treatment of advanced melanoma, where they have been shown to 
have a significant survival benefit. Emerging data have led to the ex‐
pansion of FDA‐approved indications to include renal cell carcinoma, 
urothelial carcinoma, non‐small cell lung cancer and classical Hodgkin 
lymphoma for nivolumab and non‐small cell lung cancer and head and 
neck squamous cell carcinoma for pembrolizumab. While the thera‐
peutic intent is to enhance T lymphocyte‐mediated anti‐tumour activ‐
ity in the tumour microenvironment, these agents often lead to more 
global T lymphocyte dysregulation that can result in inflammatory ad‐
verse events known as immune‐related adverse events (IRAEs).1
Gastrointestinal IRAEs are common with anti‐CTLA‐4 and anti‐PD‐1 
therapy and primarily manifest as diarrhoea or colitis characterized by 
the presence of abdominal pain, fevers or blood in stool as classified 
by NCI Common Terminology Criteria for Adverse Events (CTCAE) cri‐
teria.2 Incidence rates vary depending on the therapy and dose, with 
the highest rates reported in trials of ipilimumab at 10 mg/kg and com‐
bination ipilimumab/nivolumab therapy.3,4 In trials of ipilimumab, any 
grade diarrhoea has been reported in 30%‐46% of patients with severe 
(CTCAE grade 3‐5) diarrhoea or colitis reported in 5%‐16%.3,5 With ip‐
ilimumab therapy, symptoms of colitis typically occur after two to three 
doses.6‐8 Symptomatic colitis after anti‐PD‐1 therapy is less predictable 
with onset after 3‐14 doses in published studies.9‐11
Recently published guidelines from the American Society of 
Clinical Oncology have outlined a practical approach to the man‐
agement of checkpoint inhibitor‐induced colitis.5 It is suggested 
that mild diarrhoea (Grade 1) can be managed with anti‐diarrhoeal 
agents with consideration of temporarily holding checkpoint inhibi‐
tor therapy. Moderate to severe (Grade 2‐4) or persistent diarrhoea 
is managed with systemic high‐dose corticosteroids (1 mg/kg/day 
prednisone) followed by infliximab or vedolizumab for refractory 
disease. Diagnostic colonoscopy with possible upper endoscopy has 
been recommended in cases of Grade 2 or higher diarrhoea. Repeat 
colonoscopy has been suggested for refractory symptoms if concern 
for infection that can be associated with immunosuppressive ther‐
apy (cytomegalovirus).
Gastroenterologists are often consulted to perform lower gas‐
trointestinal endoscopic evaluation of patients with suspected se‐
vere or persistent colitis. Macroscopic findings on endoscopy are 
variable but often include erythema, friability, ulceration, granu‐
larity, though normal appearing mucosa is possible.6 Microscopic 
findings are even more variable, with the most common histo‐
logic findings including intraepithelial lymphocytes, cryptitis and 
crypt abscesses.6 While multiple case series have reported the 
predominant distribution patterns as pan‐colonic or left‐sided 
colonic, the optimal endoscopic approach to this condition has 
not been determined.6‐8 We reviewed cases of checkpoint inhib‐
itor‐induced colitis at the University of Michigan Health System 
and performed a systematic review of published studies to char‐
acterize the lower gastrointestinal distribution pattern of this 
condition to determine the diagnostic yield of flexible sigmoidos‐
copy alone compared to complete colonoscopy.
2  | METHODS
2.1 | Patient selection
A written waiver of consent was provided by the local institutional 
review board to conduct a retrospective search of the electronic 
medical record database at the University of Michigan Health 
System. We used an electronic medical record information retrieval 
tool (EMERSE) to identify all patients who had any exposure to ip‐
ilimumab, nivolumab or pembrolizumab.12 The medical records of 
these patients were manually searched to identify patients who had 
been clinically diagnosed with checkpoint inhibitor‐induced colitis. 
The medical records of these patients were then manually searched 
to identify patients who had undergone either colonoscopy or flex‐
ible sigmoidoscopy. Patients who underwent endoscopic evaluation 
for diarrhoea after exposure to a checkpoint inhibitor were selected 
for further chart review. In all patients undergoing endoscopy for 
suspected colitis, clostridium difficile and other gastrointestinal in‐
fection had been excluded by stool testing.
2.2 | Patients' clinical and endoscopic 
characteristics
Patients' key characteristics including age (at time of endoscopic 
procedure), gender, type of malignancy and checkpoint inhibi‐
tor regimen were recorded. The number of checkpoint inhibi‐
tor infusions prior to first report of diarrhoea and time to onset 
of diarrhoea from therapy initiation was recorded. The severity 
of diarrhoea at time of endoscopy was graded using the CTCAE 
(version 4.0) based on data from the medical record. Therapeutic 
data including use and timing of corticosteroids and infliximab for 
colitis management were recorded. Clinical data regarding hospi‐
talizations related to colitis, bowel perforation and need for bowel 
resection were recorded.
Endoscopy type (full colonoscopy, incomplete colonoscopy and 
flexible sigmoidoscopy) and timing relative to symptom onset were 
recorded. Endoscopic reports and images were manually reviewed 
to determine the disease distribution pattern of any gross inflamma‐
tory changes. The segments were categorised as rectum, sigmoid, 
descending colon, transverse colon, ascending colon/caecum and 
terminal ileum. Macroscopic inflammatory changes included any of 
the following: loss of vascularity, erythema, friability, granularity, 
oedema, exudates, erosions or ulceration. The lower gastrointes‐
tinal tract was categorised into three segments for histological as‐
sessment including terminal ileum, right colon and left colon. This 
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additional categorisation was used as practitioners frequently per‐
formed right colon and left colon biopsies rather than true segmental 
colonic biopsies.
2.3 | Systematic review search strategy
With the assistance of a medical librarian, a systematic literature 
search of Pubmed (through 1 March 2017) and Embase (through 1 
March 2017) was conducted for all relevant articles reporting colitis as‐
sociated with the use of the checkpoint inhibitor class of medications. 
Keywords used in the search included “Checkpoint inhibitor”, “CTLA‐4 
inhibitor”, “PD‐1 inhibitor”, “ipilimumab”, “nivolumab”, “pembrolizumab” 
or “tremelimumab” combined with “diarrhea”, “colitis”, “enterocolitis”, 
“toxicity”, “clinical trial” or “adverse event”. The title and abstract of 
studies identified in the search were reviewed by two investigators 
independently (APW and MSP) to exclude studies that did not per‐
tain to the research question. The full text of the remaining articles 
was examined to determine whether they met study selection criteria. 
Any discrepancies between investigators were addressed with a joint 
re‐evaluation of the article. If agreement between investigators could 
not be reached, a third investigator (RWS) adjudicated the discrepancy.
2.4 | Selection criteria
Studies considered in this systematic review included those with ex‐
perimental design (clinical trials) and observational design (case series, 
case reports) that met the following inclusion criteria: (a) clearly de‐
fined exposure to a medication identified as an immune checkpoint in‐
hibitor, (b) reported occurrence of diarrhoea as a complication related 
to immune checkpoint inhibitor exposure, (c) performance of lower 
gastrointestinal endoscopy for evaluation of diarrhoea and (d) suffi‐
cient description of endoscopic and histologic findings to determine 
distribution of lower gastrointestinal involvement by inflammatory 
changes attributed to immune checkpoint inhibitor‐mediated colitis. 
Inclusion was otherwise not restricted by study size or publication 
type. Meeting abstracts were included if the above criteria were met. 
When multiple studies reported on the same patient cohort, only the 
most comprehensive study was included. Studies were excluded if pa‐
tients had previous documented inflammatory bowel disease. A qual‐
ity assessment was not performed as this was a systematic review 
that mostly consisted of case series and case reports (ie, low quality). 
Figure 1 summarises the study identification and selection process.
2.5 | Data abstraction
Data were independently abstracted onto a standardized form by 
two investigators (APW and MSP). The following data were collected 
from each study: study design, year of publication, number of study 
patients, type of immune checkpoint inhibitor exposure, grade of di‐
arrhoea experienced by study patients, type of lower gastrointesti‐
nal endoscopic examination performed and pattern of distribution of 
endoscopic and histologic findings. In two studies, the type of lower 
F I G U R E  1   Systematic review flow chart
Records identified through
database searching (PUBMED and
EMBASE)
Records after duplicates removed,
screened by abstract
1 additional record identified
through other sources
Records excluded
(n = 1426)
Records excluded
(n = 405)
Full-text articles/abstracts
assessed for eligibility
Full Text (n = 38)
Abstract Only (n = 23)
Studies included in qualitative
synthesis
(n = 2590)
(n = 1892)
(n = 466)
159 Reviews, editorials, commentaries
385 No Endoscopic findings
20 No endoscopic/histologic
distribution pattern
437 Unrelated to enterocolitis
830 Unrelated to drug class
(n = 61)
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endoscopic exam (flexible sigmoidoscopy or colonoscopy) could not 
be distinguished.13,14 These studies reported left‐sided colonic find‐
ings in 100% of cases. As only left‐sided findings were reported, these 
studies were included for analysis along with cases of flexible sigmoi‐
doscopy. We characterized the clinical severity as either mild (grade 
1‐2 diarrhoea) or moderate‐severe (grade 3‐4 diarrhoea and/or use of 
systemic corticosteroids or infliximab) based on available data. The dis‐
tribution of endoscopic and/or histologic findings was categorised as 
‘any left‐sided colonic involvement’, ‘any right‐sided colonic or terminal 
ileum involvement’, ‘isolated right‐sided colonic or terminal ileum in‐
volvement’, ‘isolated transverse segmental colonic involvement’ based 
on available reported data. These categories were chosen to determine 
the type of endoscopic procedure necessary to obtain a diagnosis of 
checkpoint inhibitor‐mediated colitis.
2.6 | Statistical analysis
Our primary analysis focused on assessing endoscopic and histo‐
logic distribution of checkpoint inhibitor‐mediated colitis identified 
on lower gastrointestinal endoscopy. The pattern of involvement 
of the gastrointestinal tract was used to determine the diagnostic 
yield of flexible sigmoidoscopy as compared to full colonoscopy in 
diagnosing checkpoint inhibitor‐mediated colitis. Flexible sigmoidos‐
copy allows for evaluation of the entire left colon alone, whereas 
colonoscopy allows for evaluation of the entire colon and terminal 
ileum. Data were collected and summarised with proportions, means 
and medians as noted. The diagnostic yield of flexible sigmoidoscopy 
was calculated as the proportion of cases with any left‐sided colonic 
findings. All data were analysed using Microsoft Excel (Microsoft 
Office 2016, Microsoft, Redmond, WA).
3  | RESULTS
3.1 | Single centre patient characteristics
Between 7 January 2011 and 2 January 2017, a total of 1135 pa‐
tients were treated with checkpoint inhibitor therapy at our institu‐
tion or had been treated elsewhere with subsequent care provided 
at our institution. Physician‐reported checkpoint inhibitor colitis oc‐
curred in 8.5% (97/1135 patients) of patients. There were 25 cases 
of colitis out of 384 (6.5%) patients treated with pembrolizumab, 31 
cases out of 469 (6.6%) patients treated with ipilimumab, 11 cases 
out of 447 (2.4%) patients treated with nivolumab and 30 cases out 
of 118 (25.4%) patients treated with ipilimumab/nivolumab combi‐
nation therapy. A total of 36 patients underwent lower gastrointes‐
tinal endoscopic exam for suspected checkpoint inhibitor‐induced 
colitis. Thirty‐one patients were diagnosed with checkpoint inhibi‐
tor‐induced colitis by lower gastrointestinal endoscopy. Of the pa‐
tients without features of colitis on lower endoscopy (four flexible 
sigmoidoscopy, one colonoscopy), one patient was diagnosed with 
mycophenolate mofetil‐induced colitis, two patients were found to 
have isolated features of enteritis on subsequent upper endoscopy, 
one patient underwent empiric treatment for colitis with clinical 
improvement and one patient was clinically diagnosed with irritable 
bowel syndrome.
Clinical and demographic characteristics of the 31 patients with 
checkpoint inhibitor‐induced colitis diagnosed by lower endoscopy 
are presented in Table 1. All patients were being treated for ad‐
vanced melanoma. No patients had a history of inflammatory bowel 
disease. All patients presented with diarrhoea were characterized 
by increased frequency and/or loose consistency of bowel move‐
ments. In addition, 29% of patients reported blood in stools, 38.7% 
reported abdominal pain and 16.1% reported nausea. Most patients 
had been started on systemic immunosuppression prior to lower 
gastrointestinal endoscopy, with 19 (61.3%) patients receiving cor‐
ticosteroids for a mean 11 days prior to endoscopy. Three patients 
(9.6%) had received at least one dose of infliximab prior endoscopy.
3.2 | Endoscopic and histologic characteristics
A total of 17 (54.8%) patients with checkpoint inhibitor‐induced 
colitis underwent oral purgative bowel preparation with the inten‐
tion of performing diagnostic colonoscopy. Ultimately, five (29.4%) 
patients underwent an incomplete colonoscopy due to the severity 
of inflammation encountered in left colon in all cases. Flexible sig‐
moidoscopy was performed in 14 (45.2%) patients with a standard 
bowel preparation consisting of two tap water or fleet enemas. The 
most common endoscopic findings were erythema (93.5%), friabil‐
ity (58.6%), congestion (48.2%) and ulcers (37.9%). Consistent with 
prior studies, the histological findings were variable with the most 
common reported findings of acute inflammation (58.0%), chronic 
inflammation (41.9%), lymphocyte infiltration (19.3%) and plasma cell 
infiltration (16.1%).
The endoscopic and histologic distribution patterns are pre‐
sented in Table 2. The left colon was macroscopically abnormal in 13 
(92.8%), 5 (100.0%) and 11 (91.7%) of patients undergoing flexible 
sigmoidoscopy, incomplete colonoscopy and complete colonoscopy 
TA B L E  1   Case series patient characteristics
Case series patient characteristics (n = 31)
Age, y mean (SD) 64.9 (8.5)
Male, n (%) 26 (83.8)
Melanoma, n (%) 31 (100)
Checkpoint inhibitor regimen, n (%)
Ipilimumab 13 (41.9)
Ipilimumab + Nivolumab 12 (38.7)
Pembrolizumab 6 (19.3)
Doses prior to onset of diarrhoea, median (range) 2 (1‐20)
Time to onset of diarrhoea, days median (range) 39 (11‐460)
Diarrhoea grade, median (range) 3 (1‐4)
Corticosteroid use prior to endoscopy, n (%) 19 (61.30)
Corticosteroid duration prior to endoscopy, days 
mean (SD)
11 (2‐53)
Infliximab prior to endoscopy, n (%) 3 (9.60)
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respectively; in total 29 (93.5%) patients had macroscopic evidence 
of left‐sided disease. No patients had macroscopic abnormalities iso‐
lated to the right colon. Two patients had normal endoscopic exam‐
inations with typical features microscopically only. Microscopically, 
all patients exhibited left‐sided colonic features consistent with 
checkpoint inhibitor‐induced colitis where segmental biopsies were 
performed (29/29). In two patients undergoing colonoscopy, random 
colon biopsies only were performed and the exact disease distribu‐
tion could not be confirmed.
3.3 | Management of checkpoint inhibitor‐
induced colitis
Most patients with endoscopically diagnosed colitis (67.7%) were 
hospitalised at the time of endoscopic evaluation and 87.1% of pa‐
tients received systemic corticosteroids for a median 77 days (range 
1‐279) for treatment of colitis. A total of 19 (61.3%) patients required 
at least one dose (median 1, range 1‐3) of infliximab for treatment 
of corticosteroid‐refractory colitis. Among patients clinically di‐
agnosed with colitis who had not undergone endoscopic evalu‐
ation, 98.3% (60/61) were treated with corticosteroids and 39.3% 
patients received at least one dose of infliximab. The management 
of checkpoint inhibitor‐induced colitis was directed by the treating 
oncologists. There were two intestinal perforations and two bowel 
resections, which were likely related to checkpoint inhibitor induced 
colitis, in the group not evaluated endoscopically. A similar number 
of bowel perforations and resections occurred in the group that had 
undergone endoscopy (2/36).
3.4 | Systematic review search results
Of the 1892 unique studies identified using our search criteria, 61 
studies fulfilled our inclusion criteria and were included in the quali‐
tative analysis (38 full text articles, 23 in abstract form).6‐8,10,13‐68 
Results of our search strategy are depicted in Figure 1. Of these 
studies, 18 were case series and 43 were individual case reports.
3.5 | Systematic review patient characteristics
The included studies described the lower gastrointestinal distribution 
of 226 cases of checkpoint inhibitor‐induced colitis. Abbreviated study 
findings are presented in Table 3 with comprehensive study findings 
reported in Table S1. One hundred and twenty‐five patients under‐
went colonoscopy and 101 patients underwent flexible sigmoidos‐
copy. Clinical severity was mild in only 2.6% of cases, moderate‐severe 
in 84.1% and not able to be determined in 13.3%. By far, the most 
commonly reported treatment regimen was ipilimumab monotherapy 
(213/226 cases). There were three cases with ipilimumab/nivolumab 
combination therapy, five cases with tremelimumab, two cases with 
nivolumab and three cases with either pembrolizumab or nivolumab.
3.6 | Lower gastrointestinal distribution of colitis
Among the 125 patients with colitis who underwent colonoscopy, 
97.6% had left‐sided involvement, 86.4% had any right‐sided or ter‐
minal ileal involvement and 2.4% had isolated right‐sided colonic 
or terminal ileal involvement based on reported macroscopic and 
Case series macroscopic and microscopic distribution of colitis (n = 31)
Flexible sigmoidoscopy Incomplete colonoscopy Full colonoscopy
Macroscopic (endoscopy)
Rectum 13/14 4/5 9/12
Sigmoid 11/14 5/5 11/12
Descending 4/7 4/4 10/12
Left 13/14 5/5 11/12
Transverse 1/1 — 11/12
Ascending/
caecum
— — 10/12
Ileum — — 6/9
Right 1/1 — 11/12
Microscopic (histology)
Left 14/14 5/5 10/10a
Right — — 10/10a
TI — — 4/6
Data presented as proportion of patients with abnormal findings over number of patients with 
evaluation of specific lower gastrointestinal segment (n/n). Left side includes rectum, sigmoid and 
descending colon. Right side includes transverse colon, ascending colon, caecum and terminal 
ileum (TI).
aTwo patients in the full colonoscopy group had random colon biopsies only, therefore cannot 
determine histologic distribution. 
TA B L E  2   Case series endoscopic 
findings
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microscopic findings. Among the 101 patients with colitis who un‐
derwent flexible sigmoidoscopy, 99.0% had left‐sided involvement 
and 1.0% had isolated segmental transverse colonic involvement 
based on the reported macroscopic and microscopic findings. Taken 
together, left‐sided colonic involvement was seen in 98.2% of pa‐
tients with colitis undergoing endoscopy.
3.7 | Microscopic inflammation in the setting of 
a normal endoscopy
We identified four studies that described cases of colitis with 
microscopic evidence of inflammation but normal endoscopic 
appearance of the lower gastrointestinal tract.13,41,69,70 In 
one series of 36 patients, 36% had microscopic abnormali‐
ties alone with normal endoscopy.70 All patients in this se‐
ries had grade 3‐4 disease. A separate series of 35 patients 
identified 22.8% of patients with microscopic abnormalities 
but no macroscopic findings.69 In our cohort, there were two 
patients with microscopic findings consistent with colitis but 
normal endoscopy. Both individuals had undergone out‐pa‐
tient endoscopy and had grade 1‐2 diarrhoea. One patient had 
received ipilimumab and the other pembrolizumab. Neither 
patient had been treated with corticosteroids or infliximab 
prior to endoscopy.
TA B L E  3   Systematic review colitis distribution
Systematic review colitis distribution
Author (y) Medication (n)
Clinical severity
n
LC 
(any)
RC/TI 
(any)
RC/TI 
(isolated)
Transverse 
(isolated)Mild Moderate‐severe ND
Colonoscopy
Agarwal (2016)b IPI — — 22 22 22 22 0 0
Bamias (2017) IPI — 5 — 5 5 5 0 0
De Felice (2015) IPI — 4 — 4 4 3 0 0
Jain (2014)b IPI — 7 — 7 7 7 0 0
Klair (2016) IPI — 2 — 2 2 0 0 0
Marthey (2016) IPI — 33 — 33 32 27 ≤1 0
Rastogi (2014) IPI — 3 — 3 3 3 0 0
Satoh (2017) IPI — 2 — 2 2 2 0 0
Sidhu (2015)b IPI — 3 — 3 2 3 1 0
Tondon (2016)b IPI — 6 — 6 6 6 0 0
Verschuren (2016) IPI — 8 — 8 8 8 0 0
Single case reports IPI (25), NIV (2), IPI/
NIV (2), TRE (1)
2 27 1 30 29 22 1 0
Total 2 100 23 125 122 108 3 0
Flexible sigmoidoscopy
Bamias (2017) IPI — — 3 3 3 — — —
Hillock (2016 IPI — 12 — 12 12 — — —
Jain (2014)b IPI — 4 — 4 4 — — —
Johnston (2009) IPI (1), TRE (4) — 5 — 5 5 — — —
Lord (2010) IPI 2 7 — 9 9 — — —
Maker (2005) IPI 2 2 2 — — —
Marthey (2016) IPI — 2 4 6 6 — — —
O'Connor (2016) IPI — 7 — 7 6 — — 1
Sidhu (2015)b IPI (11), PEM or NIV (3) — 14 — 14 14 — — —
Verschuren (2016) IPI 1 18 — 19 19 — — —
Single case reports IPI (19), IPI/NIV (1) 1 19 20 20 — — —
Total 4 90 7 101 100 — — 1
Overall total 6 190 30 226 222 108 3 1
Any: indicates any involvement, Isolated: Indicates isolated involvement of designated region.
aIPI, ipilimumab; LC, left colon; ND, not determined; NIV, nivolumab; PEM, pembrolizumab; RC, right colon; TI, terminal ileum; TRE, tremelimumab. 
bIndicates abstract only. 
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3.8 | Isolated upper GI tract disease
While not a primary study outcome, we identified four reports de‐
scribing five patients with checkpoint inhibitor‐induced isolated 
upper gastrointestinal tract inflammation.50,70‐72 All patients reported 
symptomatic diarrhoea; one patient with oesophageal involvement 
also reported dysphagia. Predominant histologic features reported 
included lymphocytes and plasma cell infiltration. All patients un‐
derwent concomitant macroscopic and microscopic lower GI evalu‐
ation with endoscopy or ileocolectomy in one case. At our centre, we 
identified two patients presenting with diarrhoea after checkpoint 
inhibitor exposure with isolated upper GI inflammation (duodenum in 
both cases) with unremarkable lower gastrointestinal evaluation with 
biopsy who were determined to have checkpoint inhibitor‐induced 
enteritis.
4  | DISCUSSION
Checkpoint inhibitor‐induced colitis is a common clinical entity 
often occurring shortly after initiation of therapy in patients with 
advanced cancer. The optimal diagnostic evaluation sequence has 
not been determined. Following exclusion of alternative causes or 
infections, endoscopy is often pursued for a diagnosis. The type of 
initial endoscopic procedure pursued has relevant clinical implica‐
tions. Flexible sigmoidoscopy can be performed rapidly with mini‐
mal or no bowel preparation or procedural sedation. Colonoscopy 
requires an oral bowel preparation, often taking 24 hours to coordi‐
nate and typically is performed with sedation to address patient dis‐
comfort. Furthermore, colonoscopy has been associated with higher 
risk of colonic perforation than flexible sigmoidoscopy in several 
studies.73,74 Severe colonic inflammation may further heighten this 
risk.75 For ill hospitalised patients or patients who are evaluated on 
an out‐patient basis, sigmoidoscopy can often be performed quickly, 
more comfortably, at lower financial cost and likely lower risk of 
complication relative to colonoscopy.
We report a series of 31 patients at our institution with moder‐
ate to severe checkpoint inhibitor‐induced colitis diagnosed by lower 
gastrointestinal endoscopy. In 93.5% of patients (29/31), there was 
macroscopic evidence of left‐sided disease. No patients (0/31) had 
macroscopic abnormalities isolated to the right colon. All patients 
who underwent segmental colonic biopsies had microscopic evi‐
dence of disease in the left colon (29/29). A systematic review of the 
literature identified 226 cases of checkpoint inhibitor‐induced coli‐
tis. Left‐sided colonic involvement was present in 98.2% of patients. 
Pooling our single centre experience with the reviewed case series, 
flexible sigmoidoscopy with biopsy would be sufficient to diagnose 
>98% of patients with checkpoint inhibitor‐induced colitis (Figure 2).
The use and timing of endoscopic evaluation of suspected 
checkpoint inhibitor‐induced colitis are not uniform. At our insti‐
tution, we identified 24 patients with suspected colitis on clinical 
grounds alone who were empirically treated with corticosteroids 
and subsequently received infliximab without undergoing endos‐
copy. In a recent retrospective study comparing endoscopy and 
computerised tomography (CT) in checkpoint inhibitor‐induced 
colitis, investigators suggested that CT may be a suitable diagnostic 
tool for this condition based on concordance of abnormal findings 
on exams.76 We argue that endoscopic evaluation is important for 
several reasons in these patients. First, flexible sigmoidoscopy is a 
quick, safe, relatively low‐cost procedure that can definitively con‐
firm the diagnosis in most patients. Second, endoscopy can evalu‐
ate for cytomegalovirus infection, which can present similarly and 
F I G U R E  2   Colonic distribution of checkpoint inhibitor colitis
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has been reported in patients treated with checkpoint inhibitors 
who have received additional immunosuppression for other iRAE.31 
Third, endoscopy can evaluate for other conditions such as metas‐
tasis and other drug‐induced colitis that could present similarly. At 
our institution, endoscopy identified one patient with mycopheno‐
late mofetil colitis who had previously been managed as checkpoint 
inhibitor‐induced colitis. Fourth, two recent studies have identified 
the presence of colonic ulcers on endoscopy as a predictor for need 
for infliximab therapy, demonstrating a possible role for endoscopy 
in guiding initial immunosuppressive therapy.77,78 Finally, moderate 
to severe colitis often leads to treatment with prolonged immuno‐
suppression and withdrawal of immunotherapy, necessitating an 
accurate diagnosis.
Our study has several limitations. Most patients in our cohort 
and systematic review had severe disease with grade 3‐4 gastroin‐
testinal toxicity and were hospitalised at the time of endoscopy. The 
distribution pattern and endoscopic findings may not be reflective 
of patients with milder disease. There may be selection bias as only 
37% of patients with suspected colitis in our cohort underwent en‐
doscopic evaluation. Many patients undergo flexible sigmoidoscopy 
rather than full colonoscopy to evaluate this condition. Because of 
this, some patients with checkpoint inhibitor‐induced colitis with 
isolated right‐sided findings could have been missed and therefore 
not reported in the literature. As there were data available on 125 
patients who underwent full colonoscopy with only 2.4% of cases 
with isolated right‐sided involvement, we believe that this is rare. 
Also, studies often did not report immunosuppression exposure (ei‐
ther to treat colitis or other IRAE) prior to endoscopic exams, which 
may have affected the macroscopic and microscopic findings.
In conclusion, moderate to severe checkpoint inhibitor‐induced 
colitis predominantly involves the left colon. Patients are often 
treated with prolonged courses of corticosteroids and infliximab for 
refractory disease. Given the implications of diagnosis (checkpoint 
inhibitor treatment cessation, need for high intensity immunosup‐
pression, potential immunosuppression‐related complications), 
confidently identifying or excluding moderate to severe check‐
point inhibitor‐induced colitis is essential. Flexible sigmoidoscopy 
with biopsy is sufficient to identify >98% of cases of moderate to 
severe colitis with lower gastrointestinal involvement and should 
be considered as the primary diagnostic test after gastrointestinal 
infections are excluded. Mucosal biopsies should be obtained re‐
gardless of the macroscopic findings. If sigmoidoscopy with biopsy 
is normal, then combined upper endoscopy and ileocolonoscopy 
with biopsy can be performed to optimise diagnostic yield.
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